1
|
Wei A, Zhu GH, Qin MQ, Jia CG, Wang B, Yang J, Luo YH, Jing YF, Yan Y, Zhou X, Wang TY. [Analysis of clinical presentation and genetic characteristics of malignant infantile osteopetrosis]. Zhonghua Er Ke Za Zhi 2023; 61:1038-1042. [PMID: 37899344 DOI: 10.3760/cma.j.cn112140-20230822-00124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/31/2023]
Abstract
Objective: To investigate the clinical presentation and genetic characteristics of malignant infantile osteopetrosis. Methods: This was a retrospective case study. Thirty-seven children with malignant infantile osteopetrosis admitted into Beijing Children's Hospital from January 2013 to September 2022 were enrolled in this study. According to the gene mutations, the patients were divided into the CLCN7 group and the TCIRG1 group. Clinical characteristics, laboratory tests, and prognosis were compared between two groups. Wilcoxon test or Fisher exact test were used in inter-group comparison. The survival rate was estimated with the Kaplan-Meier method and the Log-Rank test was used to compare the difference in survival between groups. Results: Among the 37 cases, there were 22 males and 15 females. The age of diagnosis was 0.5 (0.2, 1.0) year. There were 13 patients (35%) and 24 patients (65%) with mutations in CLCN7 and TCIRGI gene respectively. Patients in the CLCN7 group had an older age of diagnosis than those in the TCIRGI group (1.2 (0.4, 3.6) vs. 0.4 (0.2, 0.6) years, Z=-2.60, P=0.008). The levels of serum phosphorus (1.7 (1.3, 1.8) vs. 1.1 (0.8, 1.6) mmol/L, Z=-2.59, P=0.010), creatine kinase isoenzyme (CK-MB) (457 (143, 610) vs. 56 (37, 82) U/L, Z=-3.38, P=0.001) and the level of neutrophils (14.0 (9.9, 18.1) vs. 9.2 (6.7, 11.1) ×109/L, Z=-2.07, P=0.039) at diagnosis were higher in the CLCN7 group than that in the TCIRG1 group. However, the level of D-dimer in the CLCN7 group was lower than that in the TCIRGI group (2.7 (1.0, 3.1) vs. 6.3 (2.5, 9.7) μg/L, Z=2.83, P=0.005). After hematopoietic stem cell transplantation, there was no significant difference in 5-year overall survival rate between the two groups (92.3%±7.4% vs. 83.3%±7.6%, χ²=0.56, P=0.456). Conclusions: TCIRGI gene mutations are more common in children with osteopetrosis. Children with TCIRGI gene mutations have younger age, lower levels of phosphorus, CK-MB, and neutrophils and higher level of D-dimer at the onset. After hematopoietic stem cell transplantation, patients with CLCN7 or TCIRGI gene mutations have similar prognosis.
Collapse
Affiliation(s)
- A Wei
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - G H Zhu
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - M Q Qin
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - C G Jia
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - B Wang
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - J Yang
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - Y H Luo
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - Y F Jing
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - Y Yan
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - X Zhou
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - T Y Wang
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| |
Collapse
|
2
|
Shi YW, Wang Y, Cao TY, Xu JH, Cui D, Wang XH, Zhu YP, Ruan Y, Han BM, Xia SJ, Jing YF. [Comparison of efficacy and safety of transurethral thulium laser vapoenucleation of prostate and transurethral thulium laser enucleation of prostate in the treatment of benign prostatic hyperplasia]. Zhonghua Yi Xue Za Zhi 2023; 103:2297-2301. [PMID: 37574825 DOI: 10.3760/cma.j.cn112137-20221203-02563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Abstract
Objective: To compare early outcomes between transurethral thulium laser vapoenucleation of prostate and transurethral thulium laser enucleation of prostate for the treatment of benign prostatic hyperplasia (BPH). Methods: Retrospective analysis was conducted on the clinical data of 1 638 BPH patients admitted to the Department of Urology of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine from January 2018 to December 2021. There were 916 patients underwent transurethral thulium laser vapoenucleation of prostate (ThuVEP group) and 722 patients underwent transurethral thulium laser enucleation of prostate (ThuLEP group). The operation time, eliminated tissue weight, surgical complications, duration of post-operative catheter implantation were compared between the two groups. The improvement of International Prostate Symptom Score (IPSS), Quality of Life Index (QoL), maximum uroflow rate (Qmax) and post-void residual urine volume (PVR) at 1 month after operation was compared between the two groups. Results: There were no significant differences in age, preoperative and 1-month postoperative prostate volume, IPSS score, QoL score, Qmax, and PVR between the ThuVEP and ThuLEP group (all P>0.05). There were no significant differences in perioperative indicators such as operation time, cutting or enucleation time, tissue crushing time, tissue weight, hemoglobin change, catheter indwelling time, and postoperative hospital stay between ThuVEP group and ThuLEP group (all P>0.05). The incidence of minor gross hematuria after extubation in the ThuVEP group was 7.8% (56/916), which was lower than 9.4% (65/722) in the ThuLEP group (P=0.026); the incidence of temporary incontinence at 1 month after surgery was 5.2% (38/916) in ThuVEP group, lower than 11.9% (86/722) in ThuLEP group (P<0.001). A total of 3 patients (0.4%) in ThuLEP group required operative intervention for severe post-operation bleeding, but none of ThuVEP group suffered from this kind of surgical complications. Conclusions: ThuVEP has similar efficacy with ThuLEP for the treatment of BPH. ThuVEP can significantly reduce the incidence of post-operation temporary urine incontinence, and has much superiority in stanching bleeding.
Collapse
Affiliation(s)
- Y W Shi
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - Y Wang
- Department of Urology, Shanghai General Hospital Jiading Branch, Shanghai Jiao Tong University School of Medicine, Shanghai 201800, China
| | - T Y Cao
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - J H Xu
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - D Cui
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - X H Wang
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - Y P Zhu
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - Y Ruan
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - B M Han
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - S J Xia
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - Y F Jing
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| |
Collapse
|
3
|
Tang XF, Jing YF, Lu W, Huang YZ, Wu NH, Luan Z. [A clinical study of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric patients with acquired severe aplastic anemia: single center experience]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:301-305. [PMID: 31104441 PMCID: PMC7343012 DOI: 10.3760/cma.j.issn.0253-2727.2019.04.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
目的 探讨单倍型造血干细胞移植(haplo-HSCT)治疗儿童获得性重型再生障碍性贫血(SAA)的疗效。 方法 回顾性分析2011年12月1日至2017年12月1日接受haplo-HSCT的59例SAA患者。 结果 ①全部59例SAA患儿中男37例、女22例,中位年龄4.5(1.2~14.8)岁,中位体重43(12~80)kg;SAA-Ⅰ型47例,SAA-Ⅱ型12例,26例为极重型再生障碍性贫血(VSAA);首次移植56例,二次移植3例。②预处理选用白消安+环磷酰胺+抗胸腺细胞球蛋白(ATG)方案或白消安+氟达拉滨+环磷酰胺+ATG方案;采用环孢素A(CsA)+霉酚酸酯+甲氨蝶呤方案预防急性GVHD;回输单个核细胞中位数为15.60(7.74~21.04)×108/kg,CD34+细胞中位数为4.86(3.74~7.14)×106/kg。③全部59例患儿均获得中性粒细胞和血小板植入。中性粒细胞植入中位时间为13(10~19)d,血小板植入中位时间为19(9~62)d。④Ⅰ~Ⅱ、Ⅲ/Ⅳ度急性GVHD发生率分别为45.76%(27/59)、13.56%(8/59),慢性GVHD发生率为8.47%(5/59)。巨细胞病毒血症发生率为59.32%(35/59)、EB病毒血症发生率为28.81%(17/59)。⑤中位随访时间30(8~80)个月,57例无病存活,2例死亡(均死于GVHD),5年总生存率、无失败生存率均为(96.4±2.5)%。 结论 haplo-HSCT是儿童SAA疗效较好的治疗方法。
Collapse
Affiliation(s)
- X F Tang
- Department of Paediatrics, Sixth Medical Center of PLA General Hospital of the People Liberation Army. Beijing 100048, China
| | - Y F Jing
- Department of Paediatrics, Sixth Medical Center of PLA General Hospital of the People Liberation Army. Beijing 100048, China
| | - W Lu
- Department of Paediatrics, Sixth Medical Center of PLA General Hospital of the People Liberation Army. Beijing 100048, China
| | - Y Z Huang
- Hematology Department Laboratory, Sixth Medical Center of PLA General Hospital of the People Liberation Army, Beijing 100048, China
| | - N H Wu
- Department of Paediatrics, Sixth Medical Center of PLA General Hospital of the People Liberation Army. Beijing 100048, China
| | - Z Luan
- Department of Paediatrics, Sixth Medical Center of PLA General Hospital of the People Liberation Army. Beijing 100048, China
| |
Collapse
|
4
|
Liu WJ, Chen K, Jing YF, Hu HS, Cheng JM, Qian WX, Liu J. A sub-megavolt anti-scattering grid: Fabrication, testing, and Monte Carlo simulation. Rev Sci Instrum 2018; 89:085119. [PMID: 30184666 DOI: 10.1063/1.5034316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 07/31/2018] [Indexed: 06/08/2023]
Abstract
X-ray flash radiography is an effective diagnostic in implosive research. While scattering reduces the contrast of radiography, the anti-scattering grids can effectively intercept the scattered radiation and acquire better images. A focused sub-megavolt grid is elaborately manufactured with the combination of lithography, etching, and laser drilling. The consistency of Monte Carlo simulations and radiographic experiments suggests a transmission of about 36% and a 1000 times improvement for the signal to scatter ratio of the grid.
Collapse
Affiliation(s)
- W J Liu
- Institute of Fluid Physics, China Academy of Engineering Physics, Mianyang, Sichuan 621990, China
| | - K Chen
- Institute of Fluid Physics, China Academy of Engineering Physics, Mianyang, Sichuan 621990, China
| | - Y F Jing
- Institute of Fluid Physics, China Academy of Engineering Physics, Mianyang, Sichuan 621990, China
| | - H S Hu
- Institute of Fluid Physics, China Academy of Engineering Physics, Mianyang, Sichuan 621990, China
| | - J M Cheng
- Institute of Fluid Physics, China Academy of Engineering Physics, Mianyang, Sichuan 621990, China
| | - W X Qian
- Institute of Fluid Physics, China Academy of Engineering Physics, Mianyang, Sichuan 621990, China
| | - J Liu
- Institute of Fluid Physics, China Academy of Engineering Physics, Mianyang, Sichuan 621990, China
| |
Collapse
|